Zafgen Pharmaceuticals (Cambridge, MA),Half Day Diet Review a company dedicated to the development of novel treatments for obesity, has announced promising results for its first human tests of the weight loss drug ZGN-433. The drug caused 24 obese women to loss approximately 2 lbs per week for one month. ZGN-433 is a methionine aminopeptidase 2 inhibitor (MetAP2) designed to change the way the body metabolizes fat.
Twenty-four women over the age of 18, with body mass indeces (BMI) between 32-45, were enrolled in the study. Different dose levels were evaluated to identify which dose could be safely tolerated in obese individuals. Subjects received either placebo or ZGN-433 intravenously twice weekly for four weeks for a total of eight doses. The volunteers were allowed to eat normally and were not counselled to exercise.
The 0.9 mg/m2 dose of ZGN-433 was well-tolerated and study volunteers lost on average 2 lbs per week, the maximally recommended rate of safe weight loss. Over 26 days, body weight was reduced by 3.1% in obese subjects receiving 0.9 mg of ZGN-433 compared to those who received placebo. Study participants also noted a decline in hunger with the 0.9 mg/m2 dose of ZGN-433.
Moreover, a significant reduction in triglyceride levels and low-density lipoprotein (LDL) cholesterol levels were observed in volunteers receiving ZGN-433. Triglycerides are the primary source of fat in the body, and overweight people tend to have much higher triglyceride levels than lean people. Elevated levels of LDL or "bad" cholesterol are also associated with obesity and an increased risk of heart disease.
https://shockingtruereviews.com/half-day-diet-review/
- Aaliawilliam's blog
- Log in or register to post comments